Clinical Value of MiR-182-5p in Lung Squamous Cell Carcinoma: a Study Combining Data from TCGA, GEO, and RT-qPCR Validation

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2018 Apr 12

PMID 29636077

Citations 18

Authors

Jie Luo

Ke Shi

Shu-Ya Yin

Rui-Xue Tang

Wen-Jie Chen

Lin-Zhen Huang

Ting-Qing Gan

Zheng-Wen Cai

Gang Chen

Affiliations

Soon will be listed here.

Abstract

Background: MiR-182-5p, as a member of miRNA family, can be detected in lung cancer and plays an important role in lung cancer. To explore the clinical value of miR-182-5p in lung squamous cell carcinoma (LUSC) and to unveil the molecular mechanism of LUSC.

Methods: The clinical value of miR-182-5p in LUSC was investigated by collecting and calculating data from The Cancer Genome Atlas (TCGA) database, the Gene Expression Omnibus (GEO) database, and real-time quantitative polymerase chain reaction (RT-qPCR). Twelve prediction platforms were used to predict the target genes of miR-182-5p. Protein-protein interaction (PPI) networks and gene ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were used to explore the molecular mechanism of LUSC.

Results: The expression of miR-182-5p was significantly over-expressed in LUSC than in non-cancerous tissues, as evidenced by various approaches, including the TCGA database, GEO microarrays, RT-qPCR, and a comprehensive meta-analysis of 501 LUSC cases and 148 non-cancerous cases. Furthermore, a total of 81 potential target genes were chosen from the union of predicted genes and the TCGA database. GO and KEGG analyses demonstrated that the target genes are involved in pathways related to biological processes. PPIs revealed the relationships between these genes, with EPAS1, PRKCE, NR3C1, and RHOB being located in the center of the PPI network.

Conclusions: MiR-182-5p upregulation greatly contributes to LUSC and may serve as a biomarker in LUSC.

Citing Articles

Transparent sparse graph pathway network for analyzing the internal relationship of lung cancer.

Jin Z, Shi Y, Zhou L Front Genet. 2024; 15:1437174.

PMID: 39411374 PMC: 11473316. DOI: 10.3389/fgene.2024.1437174.

Contributions of Circulating microRNAs for Early Detection of Lung Cancer.

Vykoukal J, Fahrmann J, Patel N, Shimizu M, Ostrin E, Dennison J Cancers (Basel). 2022; 14(17).

PMID: 36077759 PMC: 9454665. DOI: 10.3390/cancers14174221.

Clinical assessment and molecular mechanism of the upregulation of Toll-like receptor 2 (TLR2) in myocardial infarction.

Li M, Yan S, Dong H, Huang Z, Li D, Tang Y BMC Cardiovasc Disord. 2022; 22(1):314.

PMID: 35840880 PMC: 9287878. DOI: 10.1186/s12872-022-02754-y.

Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response.

Mohd Yacob A, Muhamad N, Chang K, Hisham H, Yusoff Y, Ibrahim L BMC Cancer. 2022; 22(1):332.

PMID: 35346116 PMC: 8962036. DOI: 10.1186/s12885-022-09396-5.

Prognosis and Biological Function of miR-3195 in Non-Small Cell Lung Cancer.

Lu Y, Zhang X, Zhang H, Zhu Z Cancer Manag Res. 2022; 14:169-176.

PMID: 35046724 PMC: 8761076. DOI: 10.2147/CMAR.S345618.

References

Vosa U, Vooder T, Kolde R, Vilo J, Metspalu A, Annilo T . Meta-analysis of microRNA expression in lung cancer. Int J Cancer. 2012; 132(12):2884-93. DOI: 10.1002/ijc.27981. View

Szakacs G, Paterson J, Ludwig J, Booth-Genthe C, Gottesman M . Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5(3):219-34. DOI: 10.1038/nrd1984. View

Mazieres J, Tovar D, He B, Nieto-Acosta J, Marty-Detraves C, Clanet C . Epigenetic regulation of RhoB loss of expression in lung cancer. BMC Cancer. 2007; 7:220. PMC: 2222678. DOI: 10.1186/1471-2407-7-220. View

Ioannidis J, Patsopoulos N, Evangelou E . Uncertainty in heterogeneity estimates in meta-analyses. BMJ. 2007; 335(7626):914-6. PMC: 2048840. DOI: 10.1136/bmj.39343.408449.80. View

Zhu Y, Xu B, Xia W . Hsa-mir-182 downregulates RASA1 and suppresses lung squamous cell carcinoma cell proliferation. Clin Lab. 2014; 60(1):155-9. DOI: 10.7754/clin.lab.2013.121131. View

De Bosscher K, Haegeman G, Elewaut D . Targeting inflammation using selective glucocorticoid receptor modulators. Curr Opin Pharmacol. 2010; 10(4):497-504. DOI: 10.1016/j.coph.2010.04.007. View

Giatromanolaki A, Koukourakis M, Sivridis E, Turley H, Talks K, Pezzella F . Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer. 2001; 85(6):881-90. PMC: 2375073. DOI: 10.1054/bjoc.2001.2018. View

Lu N, Cidlowski J . Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes. Mol Cell. 2005; 18(3):331-42. DOI: 10.1016/j.molcel.2005.03.025. View

Lim S, Mustapha N, Goh Y, Bakar N, Mohamed S . Metastasized lung cancer suppression by Morinda citrifolia (Noni) leaf compared to Erlotinib via anti-inflammatory, endogenous antioxidant responses and apoptotic gene activation. Mol Cell Biochem. 2016; 416(1-2):85-97. DOI: 10.1007/s11010-016-2698-x. View

10.

Zhang X, Tang W, Li R, He R, Gan T, Luo Y . Downregulation of microRNA-132 indicates progression in hepatocellular carcinoma. Exp Ther Med. 2016; 12(4):2095-2101. PMC: 5038555. DOI: 10.3892/etm.2016.3613. View

11.

Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J . STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2014; 43(Database issue):D447-52. PMC: 4383874. DOI: 10.1093/nar/gku1003. View

12.

Farazi T, Spitzer J, Morozov P, Tuschl T . miRNAs in human cancer. J Pathol. 2010; 223(2):102-15. PMC: 3069496. DOI: 10.1002/path.2806. View

13.

Zheng D, Haddadin S, Wang Y, Gu L, Perry M, Freter C . Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol. 2011; 4(6):575-86. PMC: 3160609. View

14.

Markou A, Sourvinou I, Vorkas P, Yousef G, Lianidou E . Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung Cancer. 2013; 81(3):388-396. DOI: 10.1016/j.lungcan.2013.05.007. View

15.

Huang G, Pan X, Jin Y, Wang Y, Song X, Wang C . The mechanisms and significance of up-regulation of RhoB expression by hypoxia and glucocorticoid in rat lung and A549 cells. J Cell Mol Med. 2016; 20(7):1276-86. PMC: 4929294. DOI: 10.1111/jcmm.12809. View

16.

Zhu W, Liu X, He J, Chen D, Hunag Y, Zhang Y . Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case control study. BMC Cancer. 2011; 11:393. PMC: 3183044. DOI: 10.1186/1471-2407-11-393. View

17.

Gan T, Tang R, He R, Dang Y, Xie Y, Chen G . Upregulated MiR-1269 in hepatocellular carcinoma and its clinical significance. Int J Clin Exp Med. 2015; 8(1):714-21. PMC: 4358503. View

18.

Pan L, Huang S, He R, Rong M, Dang Y, Chen G . Decreased expression and clinical significance of miR-148a in hepatocellular carcinoma tissues. Eur J Med Res. 2014; 19:68. PMC: 4258268. DOI: 10.1186/s40001-014-0068-2. View

19.

Wu X, Qian C, Yuan K . Correlations of hypoxia-inducible factor-1α/hypoxia-inducible factor-2α expression with angiogenesis factors expression and prognosis in non-small cell lung cancer. Chin Med J (Engl). 2011; 124(1):11-8. View

20.

Stenvold H, Donnem T, Andersen S, Al-Saad S, Busund L, Bremnes R . Stage and tissue-specific prognostic impact of miR-182 in NSCLC. BMC Cancer. 2014; 14:138. PMC: 3996062. DOI: 10.1186/1471-2407-14-138. View